The Indian government has heightened regulatory surveillance on the unauthorized sale and promotion of various generic versions of GLP-1 based weight loss drugs in the country. Concerns have been raised about the availability of these drugs through retail pharmacies, online platforms, wholesalers, and wellness clinics without proper medical supervision, which could pose serious health risks.
To ensure ethical pharmaceutical practices in the supply chain of Weight Loss Drug (GLP-1), the Drugs Controller of India, under the Health Ministry, has intensified regulatory surveillance. The government has warned that non-compliance will result in strict actions, including license cancellations, penalties, and legal prosecution.
In response to the emerging concerns, the drugs controller, in collaboration with state regulators, has taken targeted actions to prevent unauthorized sales and usage of these weight loss drugs. A comprehensive advisory was issued to manufacturers prohibiting any form of misleading promotion that could encourage off-label usage or mislead consumers.
Enforcement activities have been ramped up in recent weeks, with audits and inspections conducted at various entities involved in the pharmaceutical supply chain. The regulator emphasizes the importance of patient safety and advises citizens to use weight loss drugs only under the supervision of qualified medical practitioners.
